COVID _19. Multisystem inflammatory syndrome associated with COVID_19
Conditions
Interventions
Intervention 1: Intervention group (Pentoxifylline recipient + standard care): 100 patients with COVID-19 diagnosis will be included in the study according to the inclusion and exclusion criteria and
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Positive PCR test for nasopharyngeal sample or certain evidence indicating Covid-19 disease Moderate to mild symptoms onset of symptoms within 7 days Ability to swallow Age between 18 and 75
Exclusion criteria
Exclusion criteria: Shock state or multi-organ failure Chronic liver disease Chronic kidney disease Pregnancy and lactation Participation in other clinical studies Receiving drugs with severe interaction with pentoxifylline
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Procalcitonin level. Timepoint: At the beginning and end of the study. Method of measurement: Procalcitonin kit.;Serum Ferritin level. Timepoint: At the beginning and end of the study. Method of measurement: Ferritin kit.;Serum NT_ProBNP level ( Brain natriuretic peptide ). Timepoint: At the beginning and end of the study. Method of measurement: Nt_ProBNP ELISA Kit.;Serum D_dimer level. Timepoint: At the beginning and end of the study. Method of measurement: D_dimer ELISA kit.;??Serum LDH (Lactate Dehydrogenase) level. Timepoint: At the beginning and end of the study. Method of measurement: DGKC Kit.;Partial Thromboplastin Time ( PTT) and prothrombin Time (PT). Timepoint: At the beginning and end of the study. Method of measurement: PTT and PT Kit.;Saturation of Peripheral Oxygen in arterial blood ( SPO2 ). Timepoint: At the beginning and end of the study. Method of measurement: Arterial Blood Gas (ABG Test).;Serum C_ reactive protein (CRP) level. Timepoint: At the beginning and end of the study. Method of measurement: CRP ELISA Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reducing the length of hospital stay of patients. Timepoint: At the end of study. Method of measurement: Comparing the number of hospitalization days between the intervention group and control group.;Improving the quality of lung lesions. Timepoint: At the beginning and end of the study. Method of measurement: CT_Scan of lungs.;Change in the sense of smell. Timepoint: At the beginning and end of the study. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Afshin Gharekani
Tabriz University of Medical Sciences
Outcome results
None listed